New hope for hepatitis c: experimental drug combo shows promise in phase 3 trial
NCT ID NCT01753557
First seen Jan 11, 2026 · Last updated Jun 06, 2026 · Updated 24 times
Summary
This study tested a new drug called MP-424 combined with two standard hepatitis C medications (PEG-IFN Alfa-2a and RBV) in 54 adults with genotype 1 hepatitis C who either had never been treated or had relapsed after prior treatment. The main goal was to see if the virus was still undetectable 24 weeks after finishing treatment, known as a sustained viral response. The study is complete and focused on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS C(CHC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Toranomon Hospital
Kawasaki, Takatsu-ku, 213-8587, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.